UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Treatment of vulvodynia (vulvar pain of unknown cause)

Authors
Susan Kellogg Spadt, CRNP, PhD
Roya Rezaee, MD, FACOG
Sheryl Kingsberg, PhD
Section Editor
Robert L Barbieri, MD
Deputy Editor
Kristen Eckler, MD, FACOG

INTRODUCTION

Vulvodynia, or vulvar pain of an unknown cause, has a significant negative impact on a woman's health, self-esteem, relationships, quality of life, and work productivity. Women can have vulvar pain from a specific etiology, pain without an identifiable cause, or both. Treatment must therefore address a wide range of potential etiologies as well as provide an approach for women whose pain is not understood by available paradigms.

This topic will review our approach to treatment of vulvodynia. The evaluation of women with vulvar pain, approach to the woman with sexual pain, and evaluation and treatment of vulvar pain from specific etiologies are reviewed separately.

(See "Approach to the woman with sexual pain".)

(See "Clinical manifestations and diagnosis of localized vulvar pain syndrome (formerly vulvodynia, vestibulodynia, vulvar vestibulitis, or focal vulvitis)".)

(See "Clinical manifestations and diagnosis of genitourinary syndrome of menopause (vulvovaginal atrophy)".)

                                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: Jan 06, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstet Gynecol 2016; 127:745.
  2. Goldstein AT, Pukall CF, Brown C, et al. Vulvodynia: Assessment and Treatment. J Sex Med 2016; 13:572.
  3. Brotto LA, Yong P, Smith KB, Sadownik LA. Impact of a multidisciplinary vulvodynia program on sexual functioning and dyspareunia. J Sex Med 2015; 12:238.
  4. http://www.acog.org/Patients/FAQs/Vulvodynia (Accessed on October 31, 2016).
  5. Haefner HK, Collins ME, Davis GD, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005; 9:40.
  6. Arnold LD, Bachmann GA, Rosen R, et al. Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol 2006; 107:617.
  7. Khandker M, Brady SS, Vitonis AF, et al. The influence of depression and anxiety on risk of adult onset vulvodynia. J Womens Health (Larchmt) 2011; 20:1445.
  8. Edwards L. Vulvodynia. Clin Obstet Gynecol 2015; 58:143.
  9. Tersiguel AC, Bodéré C, Schollhammer M, et al. Screening for Neuropathic Pain, Anxiety and Other Associated Chronic Pain Conditions in Vulvodynia: A Pilot Study. Acta Derm Venereol 2015; 95:749.
  10. Sutton K, Pukall C, Wild C, et al. Cognitive, psychophysical, and neural correlates of vulvar pain in primary and secondary provoked vestibulodynia: a pilot study. J Sex Med 2015; 12:1283.
  11. Borghi A, Corazza M, Minghetti S, et al. Avocado and soybean extracts as active principles in the treatment of mild-to-moderate vulvar lichen sclerosus: results of efficacy and tolerability. J Eur Acad Dermatol Venereol 2015; 29:1225.
  12. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, American Society for Colposcopy and Cervical Pathology (ASCCP). Committee Opinion No 673: Persistent Vulvar Pain. Obstet Gynecol 2016; 128:e78.
  13. Amercian Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Amended 2014. https://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm (Accessed on November 04, 2016).
  14. De Andres J, Sanchis-Lopez N, Asensio-Samper JM, et al. Vulvodynia--An Evidence-Based Literature Review and Proposed Treatment Algorithm. Pain Pract 2016; 16:204.
  15. FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. II: Treatment of the patient with the short pelvic floor. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:269.
  16. FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. I: Background and patient evaluation. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:261.
  17. Travell J, Simons D. Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol 2, 1st ed, Williams and Wilkins, Baltimore 1992.
  18. Prendergast SA, Weiss JM. Screening for musculoskeletal causes of pelvic pain. Clin Obstet Gynecol 2003; 46:773.
  19. https://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm (Accessed on October 31, 2016).
  20. FitzGerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009; 182:570.
  21. Hartmann D, Nelson CA. Ten years after physical therapy for vulvodynia: are there lasting benefits? J Reprod Med 2008; 53.
  22. Bergeron S, Brown C, Lord MJ, et al. Physical therapy for vulvar vestibulitis syndrome: a retrospective study. J Sex Marital Ther 2002; 28:183.
  23. Hartmann D. Chronic vulvar pain from a physical therapy perspective. Dermatol Ther 2010; 23:505.
  24. Hartmann D. The perceived effectiveness of physical therapy treatment on women complaining of chronic vulvar pain and diagnosed with either vulvar vestibulitis syndrome or dysesthetic vulvodynia. J Womens Health Phy Ther 2001; 25:13.
  25. Gentilcore-Saulnier E, McLean L, Goldfinger C, et al. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J Sex Med 2010; 7:1003.
  26. Weiss JM. Chronic pelvic pain and myofascial trigger points. The Pain Clinic 2000; 2:13.
  27. Kellogg-Spadt S, Iorio J, Fariello J, Whirmore KE. Vaginal dilation: when its indicated and tips for teaching it. OBG Management 2012; 24:1.
  28. Hilton S, Vandyken C. The puzzle of pelvic pain - a rehabilitation framework for balancing tissue dysfunction and central sensitization. J Womens Phys Ther 2011; 35:103.
  29. Bo K, Berghmans B, Morkved S, Van Kampen M. Evidence-Based Physical Therapy for the Pelvic Floor: Bridging Science and Clinical Practice, 1st ed, Churchill Livingstone, Philadelphia 2007.
  30. Bergeron S, Khalifé S, Glazer HI, Binik YM. Surgical and behavioral treatments for vestibulodynia: two-and-one-half year follow-up and predictors of outcome. Obstet Gynecol 2008; 111:159.
  31. Bergeron S, Khalifé S, Dupuis MJ, McDuff P. A randomized clinical trial comparing group cognitive-behavioral therapy and a topical steroid for women with dyspareunia. J Consult Clin Psychol 2016; 84:259.
  32. Masheb RM, Kerns RD, Lozano C, et al. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. Pain 2009; 141:31.
  33. Brotto LA, Basson R, Smith KB, et al. Mindfulness-based group therapy for women with provoked vestibulodynia. Mindfulness 2015; 6:417.
  34. Goldfinger C, Pukall CF, Thibault-Gagnon S, et al. Effectiveness of Cognitive-Behavioral Therapy and Physical Therapy for Provoked Vestibulodynia: A Randomized Pilot Study. J Sex Med 2016; 13:88.
  35. Corsini-Munt S, Bergeron S, Rosen NO, et al. Feasibility and preliminary effectiveness of a novel cognitive-behavioral couple therapy for provoked vestibulodynia: a pilot study. J Sex Med 2014; 11:2515.
  36. Lidocaine ointment. US Food and Drug Administration (FDA) approved product information. Revised January, 2016. US National Library of Medicine. (Available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a18d2e07-fe58-4641-b03b-d9d56642f13c (Accessed on November 02, 2016)).
  37. Foster DC, Kotok MB, Huang LS, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010; 116:583.
  38. Bohm-Starke N, Brodda-Jansen G, Linder J, Danielsson I. The result of treatment on vestibular and general pain thresholds in women with provoked vestibulodynia. Clin J Pain 2007; 23:598.
  39. Estrace [package insert]. Rockaway, NJ: Warner Chilcott (US), LLC; 2011. http://www.allergan.com/assets/pdf/estrace_pi (Accessed on November 02, 2016).
  40. Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med 2013; 1:30.
  41. http://www.nva.org/what-is-vulvodynia/treatment/ (Accessed on November 14, 2016).
  42. Kao A, Binik YM, Amsel R, et al. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med 2012; 9:2066.
  43. Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag 2008; 13:243.
  44. Leclair CM, Goetsch MF, Li H, Morgan TK. Histopathologic characteristics of menopausal vestibulodynia. Obstet Gynecol 2013; 122:787.
  45. Goldstein A, Burrows L, Goldstein I. Can oral contraceptives cause vestibulodynia? J Sex Med 2010; 7:1585.
  46. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med 2014; 11:2764.
  47. Reed BD, Harlow SD, Legocki LJ, et al. Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study. BJOG 2013; 120:1678.
  48. Damsted-Petersen C, Boyer SC, Pukall CF. Current perspectives in vulvodynia. Womens Health (Lond) 2009; 5:423.
  49. Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont) 2008; 5:16.
  50. Janakiraman R, Hamilton L, Wan A. Unravelling the efficacy of antidepressants as analgesics. Aust Fam Physician 2016; 45:113.
  51. Brown C, Bachmann G, Foster D, et al. Milnacipran in provoked vestibulodynia: efficacy and predictors of treatment success. J Low Genit Tract Dis 2015; 19:140.
  52. Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Curr Pain Headache Rep 2006; 10:185.
  53. Ventolini G, Barhan S, Duke J. Vulvodynia, a step-wise therapeutic prospective cohort study. J Obstet Gynaecol 2009; 29:648.
  54. Bates CM, Timmins DJ. Vulvodynia--new and more effective approaches to therapy. Int J STD AIDS 2002; 13:210.
  55. Ben-David B, Friedman M. Gabapentin therapy for vulvodynia. Anesth Analg 1999; 89:1459.
  56. Harris G, Horowitz B, Borgida A. Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked. J Reprod Med 2007; 52:103.
  57. Reed BD, Haefner HK, Cantor L. Vulvar dysesthesia (vulvodynia). A follow-up study. J Reprod Med 2003; 48:409.
  58. Brown CS, Foster DC, Wan JY, et al. Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response. Contemp Clin Trials 2013; 36:154.
  59. Tympanidis P, Casula MA, Yiangou Y, et al. Increased vanilloid receptor VR1 innervation in vulvodynia. Eur J Pain 2004; 8:129.
  60. Baron R. Capsaicin and nociception: from basic mechanisms to novel drugs. Lancet 2000; 356:785.
  61. Steinberg AC, Oyama IA, Rejba AE, et al. Capsaicin for the treatment of vulvar vestibulitis. Am J Obstet Gynecol 2005; 192:1549.
  62. Murina F, Radici G, Bianco V. Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative? MedGenMed 2004; 6:48.
  63. Beal BR, Wallace MS. An Overview of Pharmacologic Management of Chronic Pain. Med Clin North Am 2016; 100:65.
  64. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107:125.
  65. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 2009; 6:2523.
  66. Pelletier F, Parratte B, Penz S, et al. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol 2011; 164:617.
  67. Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 2006; 51:467.
  68. Romito S, Bottanelli M, Pellegrini M, et al. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004; 58:164.
  69. Brown CS, Glazer HI, Vogt V, et al. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 2006; 51:635.
  70. Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 2008; 112:579.
  71. Poterucha TJ, Murphy SL, Rho RH, et al. Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort. Pain Physician 2012; 15:485.
  72. Pagano R, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Low Genit Tract Dis 2012; 16:394.
  73. Nyirjesy P, Sobel JD, Weitz MV, et al. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study. Sex Transm Infect 2001; 77:53.
  74. Papoutsis D, Haefner HK, Crum CP, et al. Vestibular Mast Cell Density in Vulvodynia: A Case-Controlled Study. J Low Genit Tract Dis 2016; 20:275.
  75. Eppsteiner E, Boardman L, Stockdale CK. Vulvodynia. Best Pract Res Clin Obstet Gynaecol 2014; 28:1000.
  76. Foster DC, Hasday JD. Elevated tissue levels of interleukin-1 beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol 1997; 89:291.
  77. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982; 129:1803.
  78. Murina F, Tassan P, Roberti P, Bianco V. Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine. An alternative approach. J Reprod Med 2001; 46:713.
  79. Segal D, Tifheret H, Lazer S. Submucous infiltration of betamethasone and lidocaine in the treatment of vulvar vestibulitis. Eur J Obstet Gynecol Reprod Biol 2003; 107:105.
  80. Dede M, Yenen MC, Yilmaz A, Baser I. Successful treatment of persistent vulvodynia with submucous infiltration of betamethasone and lidocaine. Eur J Obstet Gynecol Reprod Biol 2006; 124:258.
  81. Intrarosa [package insert]. Quebec City, Canada: Endoceuticals Inc; 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf (Accessed on December 21, 2016).
  82. Nahin RL, Boineau R, Khalsa PS, et al. Evidence-Based Evaluation of Complementary Health Approaches for Pain Management in the United States. Mayo Clin Proc 2016; 91:1292.
  83. Curran S, Brotto LA, Fisher H, et al. The ACTIV study: acupuncture treatment in provoked vestibulodynia. J Sex Med 2010; 7:981.
  84. Powell J, Wojnarowska F. Acupuncture for vulvodynia. J R Soc Med 1999; 92:579.
  85. Danielsson I, Sjöberg I, Ostman C. Acupuncture for the treatment of vulvar vestibulitis: a pilot study. Acta Obstet Gynecol Scand 2001; 80:437.
  86. Schlaeger JM, Xu N, Mejta CL, et al. Acupuncture for the treatment of vulvodynia: a randomized wait-list controlled pilot study. J Sex Med 2015; 12:1019.
  87. Pukall CF, Young RA, Roberts MJ, et al. The vulvalgesiometer as a device to measure genital pressure-pain threshold. Physiol Meas 2007; 28:1543.
  88. Murina F, Karram M, Salvatore S, Felice R. Fractional CO2 Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. J Sex Med 2016; 13:1915.